Key Takeaways
- • The federal government is delaying final legislation on a startup tax incentive mechanism until late 2027, with a consultation paper outlining eligibility criteria: firms must maintain annual turnover under $50 million, operate for less than a decade, and issue equity after June 30, 2027.
- • A significant market transition occurs July 1, replacing a flat 50% capital gains tax discount with cost base indexation and a 30% minimum tax rate, reshaping tax treatment across venture capital portfolios.
- • Bailador Technology Investments reported pre-tax NTA of $1.67 per share (April 30), with a $5 million DASH investment now valued at $37.6 million, demonstrating concentrated exposure in expansion-stage technology bets.
- • Neuren Pharmaceuticals generated $65 million in royalty income from DAYBUE in 2025 (15% YoY increase), with full-year 2026 guidance of $70–77 million, signaling sustained revenue growth in biotech aligned with longer clinical development horizons discussed in the treasury review.
- • Touch Ventures reported a net financial loss of $15.42 million for full-year 2025, reflecting the challenging exit environment and valuation pressures in growth-stage venture portfolios.
Summary
The federal government has released a consultation paper establishing an alternative tax mechanism designed to preserve capital gains concessions for eligible early-stage startups, though final legislation will not arrive until late 2027. The proposed framework targets independent firms with annual turnover below $50 million that have operated for fewer than a decade and issue equity after June 30, 2027. This delayed implementation reflects ongoing policy deliberation around venture capital incentives and their role in stimulating startup formation and growth.
The timing of this announcement carries material consequences for the broader market. Beginning July 1, the existing flat 50% capital gains discount will be replaced by cost base indexation paired with a 30% minimum tax rate—a structural shift that will alter the after-tax returns for venture capital investors and founders across all portfolio stages. This transition is expected to reshape capital allocation decisions and carry-value assessments within listed venture funds and investment vehicles.
Among key market participants, Bailador Technology Investments (ASX:BTI) reported pre-tax net tangible asset backing of $1.67 per share and post-tax NTA of $1.55 per share for the period ended April 30. The fund recently completed a $5 million investment in wealth management platform DASH, which has appreciated significantly to a carrying value of $37.6 million, reflecting strong performance in a concentrated technology position. Touch Ventures (ASX:TVL), by contrast, posted a net financial loss of $15.42 million for full-year 2025, illustrating ongoing pressure in the growth-stage venture ecosystem.
Biopharmaceutical holdings demonstrate diverging fortunes. Neuren Pharmaceuticals generated $65 million in royalty income from its core drug DAYBUE during 2025, a 15% year-on-year increase, with full-year 2026 guidance projected between $70 million and $77 million. This sustained revenue growth aligns with the longer clinical development horizons referenced in the treasury consultation paper. Telix Pharmaceuticals, operating in commercial-stage precision medicine, continues to develop targeted radiation treatments and diagnostic imaging agents as part of the broader biopharmaceutical allocation strategy.
The timing of this announcement carries material consequences for the broader market. Beginning July 1, the existing flat 50% capital gains discount will be replaced by cost base indexation paired with a 30% minimum tax rate—a structural shift that will alter the after-tax returns for venture capital investors and founders across all portfolio stages. This transition is expected to reshape capital allocation decisions and carry-value assessments within listed venture funds and investment vehicles.
Among key market participants, Bailador Technology Investments (ASX:BTI) reported pre-tax net tangible asset backing of $1.67 per share and post-tax NTA of $1.55 per share for the period ended April 30. The fund recently completed a $5 million investment in wealth management platform DASH, which has appreciated significantly to a carrying value of $37.6 million, reflecting strong performance in a concentrated technology position. Touch Ventures (ASX:TVL), by contrast, posted a net financial loss of $15.42 million for full-year 2025, illustrating ongoing pressure in the growth-stage venture ecosystem.
Biopharmaceutical holdings demonstrate diverging fortunes. Neuren Pharmaceuticals generated $65 million in royalty income from its core drug DAYBUE during 2025, a 15% year-on-year increase, with full-year 2026 guidance projected between $70 million and $77 million. This sustained revenue growth aligns with the longer clinical development horizons referenced in the treasury consultation paper. Telix Pharmaceuticals, operating in commercial-stage precision medicine, continues to develop targeted radiation treatments and diagnostic imaging agents as part of the broader biopharmaceutical allocation strategy.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.